Introduction 43 Invasive bacteria, such as Haemophilus influenza type b (Hib), 44 Neisseria meningitides and Streptococcus pneumonia, the most important 45 antigen is polysaccharide on the surface of them. Capsular polysaccharide 46 is thymus independent antigen; immunization of infants and young 47 children with these antigens does not induce well and long-lasting 48 protective levels of serum antibodies. The success of Hib 49 glycol-conjugate vaccine highlighted the advantages of converting 50 polysaccharides into T-dependent antigens by chemical conjugation to 51 carrier proteins. Tetanus toxoid, diphtheria toxoid and the non-toxic 52 mutant of diphtheria toxin, CRM197 are commonly used as protein 53 carrier. With the increasing of polysaccharide conjugate vaccines, the 54 development of new protein carrier is necessary for avoiding immune tolerance, immune interference or immune suppression due to repeated 56 using the same carrier (1, 2) . In addition, the imperfection of the 57 polysaccharide and conjugate vaccine is that the protection of them can 58 not cover all serotypes of the bacteria strains. Serotype conversion limits 59 their development and decreases their immune protecting coverage. Thus 60 increasing the selection of carrier protein or developing the new 61 conjugate vaccine without serotype limitation is important and necessary 62 in future. 63 In order to solve the above problems, we chose pneumococcal 64 surface protein A (PspA) as research subject. PspA is virulence associated but lower about clades from different families. Based on its structural 78 diversity, it has been suggested that PspA-based vaccine should contain at 79 least one clade from each of the two major families in order to elicit 80 broad protection (9). 81 In our study, different clades of recombinant PspA protein (clade1, 82 clade2 and clade3) were prepared and conjugated to group A 83 meningococcal polysaccharide (GAMP) as carrier protein to make 84 available a compounds, which not only prevent epidemic cerebrospinal 85 meningitis but also has the potential to provide protection from 86 Streptococcus pneumonia. The immune effects，including humoral and 87 cellular immune responses were assessed after being immune to mice. In 88 this article, we focused on the ability of the conjugates to prevent 89 meningococcal infection, and pneumococcal infection will be covered in 90 a follow-up study. and PspA3-GAMP, prepared with cyanogen bromide activation method. 200 The content of protein and polysaccharide were tested by the methods 201 described in Chinese pharmacopoeia (10). The ratio of polysaccharide 202 and protein were calculated according to their concentration. Table 1   203 shows the results. The ratio in the three GAMP-PspA conjugates was similar, P＞0.05, which were higher than that of in GAMP-TT conjugates, P < 0.05. There 232 were no significant differences between the three un-conjugated PspA 233 groups and the three GAMP-PspA conjugates, P＞0.05. 
Discussion

247
According to the genome sequences of corresponding protein in 248 GenBank, we adopt the method of chemical synthesis for our targeting 249 genes. This method can omit the bacterial culture process, and can also 250 obtain any kind of bacteria gene sequences that can be found in GenBank. (12, 13) . For TT, another possibility is that the 292 destruction of T cell epitope in the chemical detoxification process, which 293 affecting its immunogenicity (14). The exact cause remains to be 294 confirmed. 295 In order to evaluate the cellular immune response following the third 296 immunization with conjugates and un-conjugates, FCM methods were used. For Th1/Th2 ratio detected by FCM, compared with un-conjugated 298 GAMP and PBS control, the ratio in groups of conjugates were 299 significantly higher, P < 0.05. The above results indicated that the carrier 300 protein conjugated with GAMP can activate the cellular immune 301 response. 302 Serum bactericidal assay is mainly detecting the activity of 303 functional antibody in the serum, which is the most direct method in the 304 evaluation of meningococcal polysaccharide vaccine efficacy. It has 305 proved it is associated with the protection of vaccine in the 1860s (15-18), 306 and it has become the gold standard for evaluation of meningococcal 307 vaccine efficacy. The results of SBA showed that the bactericidal 308 activities of the conjugates were significantly stronger than that of 309 un-conjugated GAMP, and the potency of GAMP-PspA1 was higher than 310 that of GAMP -TT, P < 0.05; other PspA conjugates (PspA2, PspA3) had 311 no statistical differences compared with GAMP-TT group, P＞0.05. 312 In conclusion, described here is a procedure for producing a GAMP 192-260. Microb Pathog 1994; 17:323-37. 351 
